Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
37,871,761
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
2,951,398
-
Shares change
-
+419,312
-
Total reported value, excl. options
-
$11,453,000
-
Value change
-
-$36,263,645
-
Put/Call ratio
-
67.8%
-
Number of buys
-
16
-
Number of sells
-
-10
-
Price
-
$3.88
Significant Holders of Anixa Biosciences Inc - Common Stock (ANIX) as of Q2 2021
38 filings reported holding ANIX - Anixa Biosciences Inc - Common Stock as of Q2 2021.
Anixa Biosciences Inc - Common Stock (ANIX) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,951,398 shares
of 37,871,761 outstanding shares and own 7.79% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1,302,231 shares), UBS Group AG (687,302 shares), GEODE CAPITAL MANAGEMENT, LLC (213,804 shares), RENAISSANCE TECHNOLOGIES LLC (124,499 shares), BlackRock Inc. (118,029 shares), TWO SIGMA ADVISERS, LP (61,638 shares), NORTHERN TRUST CORP (61,282 shares), MORGAN STANLEY (56,631 shares), RAYMOND JAMES & ASSOCIATES (54,056 shares), and TWO SIGMA INVESTMENTS, LP (52,450 shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.